MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock, net...
$228,351K
Proceeds from issuance of
pre-funded warrants, net...
$5,855K
Proceeds from exercise of
stock options
$281K
Net cash provided by
financing activities
$234,487K
Net increase in
cash, cash...
$16,161K
Canceled cashflow
$218,326K
Maturities of short-term
investments
$50,000K
Stock-based compensation
expense
$4,706K
Accounts receivable
-$1,367K
Non-cash lease expense
-$1,132K
Depreciation and
amortization
$214K
Accounts payable
$67K
Amortization of intangible
assets
$37K
Net cash (used in)
provided by investing...
-$192,777K
Net cash used in
operating activities
-$25,549K
Canceled cashflow
$50,000K
Canceled cashflow
$7,523K
Purchases of short-term
investments
$242,777K
Net income (loss)
-$18,248K
Deferred revenue
-$9,612K
Accrued liabilities and
other long-term...
-$3,599K
Prepaid expenses and
other assets
$887K
Accretion of discounts on
short-term investments
$726K
Back
Back
Cash Flow
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)
source: myfinsight.com